The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.5, Iss.2, 2000-07, pp. : 161-199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Concepts in Ras-directed therapy

By Kloog Y. Cox A.D. Sinensky M.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 12, 1999-12 ,pp. : 2121-2140

Informa Healthcare

Access to resources Recommend Favorite

Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases

Current Drug Targets, Vol. 8, Iss. 2, 2007-02 ,pp. : 217-235

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting aggregation in the development of therapeutics for the treatment of Huntington’s disease and other polyglutamine repeat diseases

By Steffan Joan S Thompson Leslie Michels

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 2, 2003-04 ,pp. : 201-213

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal Antibody-Directed Cytotoxic Therapy: Potential in Malignant Diseases of Aging

By Panousis C. Pietersz G.A.

Drugs & Aging, Vol. 15, Iss. 1, 1999-07 ,pp. : 1-13

Adis International

Access to resources Recommend Favorite

Protein farnesyltransferase inhibitors

By Head Julia E Johnston Stephen RD

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 1, 2003-05 ,pp. : 163-178

Informa Healthcare

Access to resources Recommend Favorite